Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tretinoin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 5/20 | 1.00 |
| ▸ | RARA known ✓ | P10276 | 4/20 | 1.00 |
| ▸ | RARB known ✓ | P10826 | 4/20 | 1.00 |
| ▸ | RARG known ✓ | P13631 | 4/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 2/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | APP | P05067 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RORC | P51449 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tretinoin SCHEMBL942726 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL12494390 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL4321428 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL10276943 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982760 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL9856240 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL24982761 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL5324134 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Isotretinoin SCHEMBL20603086 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA | |
| Tretinoin SCHEMBL3952 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022034427-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 4-OXOISOTRETINOIN | AUROBINDO PHARMA LTD (IN) | 2022-02-17 | — | — | WO | disclosed |
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10265288-B2 | Methods and compositions for the treatment of proliferative disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-07 | — | — | US | disclosed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150044278-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20140086909-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-7763748-B2 | Process for preparation of highly pure isotretinoin | IPCA LABORATORIES LIMITED (IN) | 2010-07-27 | — | — | US | disclosed |
| US-7763748-B2 | Process for preparation of highly pure isotretinoin | IPCA LABORATORIES LIMITED (IN) | 2010-07-27 | — | — | US | disclosed |
| US-20080207946-A1 | PROCESS FOR PREPARATION OF HIGHLY PURE ISOTRETINOIN | IPCA LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| US-20080207946-A1 | PROCESS FOR PREPARATION OF HIGHLY PURE ISOTRETINOIN | IPCA LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1453545-B1 | WATER-SOLUBLE POLYMER CONJUGATES OF RETINOIC ACID | NEKTAR THERAPEUTICS AL CORP (US) | 2007-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | PIN1, AS3MT, PML | RXRA 27/4885RARA 8/4885RARB 4/4885 |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | PIN1, AS3MT, PML | RXRA 27/4885RARA 8/4885RARB 4/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | RXRA 5/4885RARA 3/4885RARB 2/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | RXRA 5/4885RARA 3/4885RARB 2/4885 |
| US-20080207946-A1 | PROCESS FOR PREPARATION OF HIGHLY PURE ISOTRETINOIN | RARA, RARB, RARG | RXRA 9/4885RARA 1/4885RARB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.